Stevanato Group (STVN) Investor presentation summary

Operational excellence and market leadership

• Over 70 years, established as a leading provider of mission-critical solutions for the biopharma industry, with a global presence and a strong track record of growth, reaching €1,104M in FY24 revenue and a 15% revenue CAGR from FY19 to FY24.

• Serves 23 of the top 25 pharma companies, with 5,600 employees and over 700 customers worldwide.

• Holds #1 market positions in ready-to-use vials and pen cartridges, and #2 in pre-filled syringes.

Strategic expansion and innovation

• Expanded global footprint with 13 production sites and ongoing investments in new plants in the US, Italy, China, Mexico, Brazil, and Slovakia.

• Seven decades of innovation, including patented EZ-fill® technology, analytical services, and integrated systems across the value chain.

• Focused on high-value solutions (HVS), which grew from 17% to 38% of revenue between 2019 and 2024.

Business model and value proposition

• Delivers integrated end-to-end solutions through two segments: Biopharmaceutical & Diagnostic Solutions (85% of 2024 revenue) and Engineering (15%).

• Unique offering combines products, services, and processes, providing competitive advantage and high value to customers, especially in biologics and injectables.

• Supports customers from drug development through life-cycle management, with a strong focus on compliance and regulatory support.